1.Neoadjuvant radiohormonal therapy for oligo-metastatic prostate cancer: safety and efficacy outcomes from an open-label, dose-escalation, single-center, phase I/II clinical trial.
Yifan CHANG ; Xianzhi ZHAO ; Yutian XIAO ; Shi YAN ; Weidong XU ; Ye WANG ; Huojun ZHANG ; Shancheng REN
Frontiers of Medicine 2023;17(2):231-239
To evaluate the safety and efficacy of neoadjuvant radiohormonal therapy for oligometastatic prostate cancer (OMPC), we conducted a 3 + 3 dose escalation, prospective, phase I/II, single-arm clinical trial (CHiCTR1900025743), in which long-term neoadjuvant androgen deprivation was adopted 1 month before radiotherapy, comprising intensity modulated radiotherapy to the pelvis, and stereotactic body radiation therapy to all extra-pelvic bone metastases for 4-7 weeks, at 39.6, 45, 50.4, and 54 Gy. Robotic-assisted radical prostatectomy was performed after 5-14 weeks. The primary outcome was treatment-related toxicities and adverse events; secondary outcomes were radiological treatment response, positive surgical margin (pSM), postoperative prostate-specific antigen (PSA), pathological down-grading and tumor regression grade, and survival parameters. Twelve patients were recruited from March 2019 to February 2020, aging 66.2 years in average (range, 52-80). Median baseline PSA was 62.0 ng/mL. All underwent RARP successfully without open conversions. Ten patients recorded pathological tumor down-staging (83.3%), and 5 (41.7%) with cN1 recorded negative regional lymph nodes on final pathology. 66.7% (8/12) recorded tumor regression grading (TRG) -I and 25% (3/12) recorded TRG-II. Median follow-up was 16.5 months. Mean radiological progression-free survival (RPFS) was 21.3 months, with 2-year RPFS of 83.3%. In all, neoadjuvant radiohormonal therapy is well tolerated for oligometastatic prostate cancer.
Male
;
Humans
;
Prostatic Neoplasms/radiotherapy*
;
Prostate-Specific Antigen/therapeutic use*
;
Neoadjuvant Therapy
;
Androgen Antagonists/therapeutic use*
;
Prospective Studies
2.Eligibility of C-BIOPRED severe asthma cohort for type-2 biologic therapies.
Zhenan DENG ; Meiling JIN ; Changxing OU ; Wei JIANG ; Jianping ZHAO ; Xiaoxia LIU ; Shenghua SUN ; Huaping TANG ; Bei HE ; Shaoxi CAI ; Ping CHEN ; Penghui WU ; Yujing LIU ; Jian KANG ; Yunhui ZHANG ; Mao HUANG ; Jinfu XU ; Kewu HUANG ; Qiang LI ; Xiangyan ZHANG ; Xiuhua FU ; Changzheng WANG ; Huahao SHEN ; Lei ZHU ; Guochao SHI ; Zhongmin QIU ; Zhongguang WEN ; Xiaoyang WEI ; Wei GU ; Chunhua WEI ; Guangfa WANG ; Ping CHEN ; Lixin XIE ; Jiangtao LIN ; Yuling TANG ; Zhihai HAN ; Kian Fan CHUNG ; Qingling ZHANG ; Nanshan ZHONG
Chinese Medical Journal 2023;136(2):230-232
3.Dynamic disease manifestations among individuals infected with SARS-CoV-2 Omicron variant.
Peiqin WANG ; Xinwei FENG ; Zhiwen SHI ; Zimao JIANG ; Luping WANG ; Xin GAO ; Hui QI ; Min CHEN ; Jian WANG ; Weifen XIE
Chinese Medical Journal 2023;136(22):2768-2770
Humans
;
COVID-19
;
SARS-CoV-2
5.A comparison of perioperative outcomes between extraperitoneal robotic single-port and multiport radical prostatectomy with the da Vinci Si Surgical System.
Guan-Qun JU ; Zhi-Jun WANG ; Jia-Zi SHI ; Zong-Qin ZHANG ; Zhen-Jie WU ; Lei YIN ; Bing LIU ; Lin-Hui WANG ; Dong-Liang XU
Asian Journal of Andrology 2021;23(6):640-647
To evaluate outcomes between extraperitoneal robotic single-port radical prostatectomy (epR-spRP) and extraperitoneal robotic multiport radical prostatectomy (epR-mpRP) performed with the da Vinci Si Surgical System, comparison was performed between 30 single-port (SP group) and 26 multiport (MP group) cases. Comparisons included operative time, estimated blood loss (EBL), hospital stay, peritoneal violation, pain scores, scar satisfaction, continence, and erectile function. The median operation time and EBL were not different between the two groups. In the SP group, the median operation time of the first 10 patients was obviously longer than that of the latter 20 patients (P < 0.001). The median postoperative hospital stay in the SP group was shorter than that in the MP group (P < 0.001). The rate of peritoneal damage in the SP group was less than that in the MP group (P = 0.017). The pain score and overall need for pain medications in the SP group were lower than those in the MP group (P < 0.001 and P = 0.015, respectively). Patients in the SP group were more satisfied with their scars than those in the MP group 3 months postoperatively (P = 0.007). At 3 months, the cancer control, recovery of erectile function, and urinary continence rates were similar between the two groups. It is safe and feasible to perform epR-spRP using the da Vinci Si surgical system. Therefore, epR-spRP can be a treatment option for localized prostate cancer. Although epR-spRP still has a learning curve, it has advantages for postoperative pain and self-assessed cosmesis. In the absence of the single-port robotic surgery platform, we can still provide minimally invasive surgery for patients.
Aged
;
Blood Loss, Surgical/statistics & numerical data*
;
Humans
;
Male
;
Middle Aged
;
Outcome Assessment, Health Care/statistics & numerical data*
;
Perioperative Medicine/statistics & numerical data*
;
Prostatectomy/methods*
;
Prostatic Neoplasms/surgery*
;
Quality Assurance, Health Care/statistics & numerical data*
;
Robotic Surgical Procedures/statistics & numerical data*
6. Analysis of the effective components and mechanism of Yufang Fangji II for prevention of COVID-19 based on UHPLC-Q-TOF/MS and network pharmacology
Guangyang JIAO ; Doudou HUANG ; Yong CHEN ; Deduo XU ; Wansheng CHEN ; Feng ZHANG ; Tianyi YU ; Bolong WANG ; Shi QIU ; Wansheng CHEN
Chinese Journal of Clinical Pharmacology and Therapeutics 2021;26(10):1127-1145
AIM: The main chemical components of Yufang Fangji II (Hubei Fang) of COVID-19 were studied systematically and combined with network pharmacology to provide a reference for the study of its effective substances. METHODS: Ultra high-performance liquid chromatography quadrupole time of flight mass spectrometry (UHPLC-Q-TOF/MS) was applied to identify the absorbed components of the prescription in rat plasma. TCMSP database and Swiss Target Prediction data platform were used to predict the target of the identified blood components, and network visualization software Cytoscape 3.7.2 was used draw the association network diagram, and GO enrichment analysis and KEGG pathway enrichment analysis were conducted for the key targets. With the help of CB-Dock online molecular docking platform, the molecular docking of key targets and blood entering compounds was carried out, and the docking combination with good affinity value was displayed by ligplot software to verify the preventive effect of Yufang Fangji II on COVID-19. RESULTS: A total of 52 chemical components identified in the prescription, in which 13 components were absorbed in the rat plasma as the prototype, and they were from Astragalus membranaceus, Atractylodes macrocephala, Saposhnikoviae Radix, Lonicerae Japonicae Flos, and Citri Reticulatae Pericarpium, respectively. These compounds were recognized to act on 17 core targets, including mapk3, TNF and other targets related to inflammation, MPO and other targets related to oxidative stress, VEGFR, KDR and other targets related to vascular endothelium. The results of molecular docking showed that the absorbed components had good binding activity with the key targets. CONCLUSION: Compounds in Yufang Fangji II are involved in regulating inflammation, oxidative stress, vascular and cellular physiological activities, which have preventive effects on COVID-19 through regulating IL-17, PI3K Akt, MAPK and other pathways.
7.Study on the anti-RSV activity and mechanism of Mentha haplocalyx Briq.
Chenxiao SHI ; Jiaxin XU ; Hao GUO ; Changzheng ZHOU
International Journal of Traditional Chinese Medicine 2020;42(6):562-566
Objective:To explore the inhibitory effects of Mentha haplocalyx Briq. With different extraction methods on respiratory syncytial virus (RSV) in vitro and antiviral mechanism of it seffective parts. Methods:By using the virus infection model in vitro to detect the cytopathic effect (CPE) of the anti-RSV effect of Mentha haplocalyx Briq. in vitro. Make the anti-RSV therapeutic index (TI) in vitroas the index to screen the extraction method of mint and the macro-porous adsorption resin, so as to determine the best extraction method, and the best macroporous adsorption resin was used for separation and purification. Elution with different concentrations of eluent was used to determine the effective parts of Mentha haplocalyx Briq. resisting RSV. The antiviral mechanism was analyzed by different administration methods. Results:The supernatant of Mint after water extraction and alcohol precipitation had the strongest inhibitory effect on RSV, with TI value of 37.58; HPD100 resin had the best separation and purification effect on the supernatant, and 25% ethanol elution site had the best effect, and the TI value was 57.8. The effective substances were determined to be polyphenols by physicochemical identification reaction. After the effective parts are mixed with the virus, the antiviral experiment is the best.Conclusions:The supernatant of mint after water extraction and alcohol precipitation was adsorbed by HPD100, and 25% ethanol eluent had the best anti-RSV effect, with preventive and therapeutic effects.
8.Molecular genetics of medicinal plants, past achievement, and new era.
Shi-Lin CHEN ; Wei SUN ; Wen-Guang WU ; Wan-Sheng CHEN ; Ying WANG ; Yang DONG ; Yi-Fei LIU ; Zhi-Chao XU ; Chao SUN ; Qing-Gang YIN ; Yong-Qing LI ; Ming LUO ; Ying XIAO ; Hui-Hua WAN
China Journal of Chinese Materia Medica 2020;45(23):5577-5588
Unraveling the genetic basis of medicinal plant metabolism and developmental traits is a long-standing goal for pharmacologists and plant biologists. This paper discusses the definition of molecular genetics of medicinal plants, which is an integrative discipline with medicinal plants as the research object. This discipline focuses on the heredity and variation of medicinal plants, and elucidates the relationship between the key traits of medicinal plants(active compounds, yield, resistance, etc.) and genotype, studies the structure and function, heredity and variation of medicinal plant genes mainly at molecular level, so as to reveal the molecular mechanisms of transmission, expression and regulation of genetic information of medicinal plants. Specifically, we emphasize on three major aspects of this discipline.(1)Individual and population genetics of medicinal plants, this part mainly highlights the genetic mechanism of the domestication, the individual genomics at the species level, and the formation of genetic diversity of medicinal plants.(2)Elucidation of biosynthetic pathways of active compounds and their evolutionary significance. This part summarizes the biosynthesis, diversity and molecular evolution of active compounds in medicinal plants.(3) Molecular mechanisms that shaping the key agronomic traits by internal and external factors. This part focuses on the accumulation and distribution of active compounds within plants and the regulation of metabolic network by environmental factors. Finally, we prospect the future direction of molecular genetics of medicinal plants based on the rapid development of multi-omics technology, as well as the application of molecular genetics in the future strategies to achieve conservation and breeding of medicinal plants and efficient biosynthesis of active compounds.
Biosynthetic Pathways
;
Genomics
;
Molecular Biology
;
Plant Breeding
;
Plants, Medicinal
9. Application of L3 skeletal muscle index in evaluating prognosis of diseases
Academic Journal of Second Military Medical University 2019;40(4):420-425
L3 skeletal muscle index (L3 SMI) is an emerging nutritional assessment tool. It has been well documented that L3 SMI can correctly reflect body skeletal muscle mass, and can be used to evaluate the prognosis of sarcopenia, chronic liver disease and many malignant tumors. Moreover, it can also be used to predict some surgical complications. This review sums up the recent advances of L3 SMI in evaluating prognosis of diseases.
10. Preliminary study on the safety of liver transplantation recipients with Rh blood group mismatching
Shaohua SONG ; Yanling WANG ; Hao LIU ; Junfeng DONG ; Keyan SUN ; Jiayong DONG ; Fei TENG ; Wenyuan GUO ; Xiaomin SHI ; Guoshan DING ; Zhiren FU
Chinese Journal of Organ Transplantation 2019;40(9):553-557
Objective:
To explore the safety of liver transplantation recipients with Rh blood group mismatchming.
Methods:
From May 2005 to December 2018, 1 546 cases of liver transplantation in our hospital were retrospectively analyzed. Among these cases, 5 cases of Rh blood group mismatched were Rh(-) recipients receiving Rh(+ ) donor liver. For each Rh blood group mismatched liver transplantation, 5 patients received the same Rh blood group liver allograft were matched according to a certain principle and were defined as Rh-mismatch group and Rh-match group respectively. The serum alanine aminotransferase (ALT), aspartate aminotransferase(AST)and creatinine(SCr)were compared between two groups at Days 7 & 14 post-operation. Serum total bilirubin(TB), gamma-glutamyl transpeptidase(GGT)were compared between two groups at Month 1, 6 & 12 post-operation. Hemoglobin (Hb)were compared between two groups Month 1, 3 & 6 post-operation. The rates of infection, vascular complications and acute rejection was also compared. Indirect antiglobulin test (IAT)was used for detecting the production of anti-RhD antibody in patients in Rh-mismatch group at Month 1, 6 & 12 post-operation.
Results:
At the mentioned time, no significant inter-group difference existed in serum ALT, AST, SCr, TB, GGT and blood Hb levels(all

Result Analysis
Print
Save
E-mail